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Underlying diseases might be risk factors for poor prognosis in patients with coronavirus dis-
ease (COVID-19); however, we still do not know whether these diseases are independent
factors affecting prognosis, which type of underlying diseases are risk factors, and which
type of clinical outcomes are affected. We retrospectively reviewed cohort data from 7,590
de-identified patients with COVID-19 who were diagnosed using severe acute respiratory
syndrome-coronavirus-2 RNA polymerase chain reaction test up to May 15, 2020. We used
linked-medical claims data provided by the Health Insurance Review and Assessment Ser-
vice in South Korea. Underlying diseases were identified using the diagnostic codes in the
patients’ files from January 1, 2019 to December 31, 2019. The total mortality rate was 3.0%
in patients with COVID-19. After adjusting for age, sex, and concomitant chronic conditions,
we found that congestive heart failure, chronic pulmonary diseases, diabetes without
chronic complications, renal diseases, and malignancy were factors that significantly
increased the cost of treatment. Cerebrovascular disease, chronic pulmonary disease, and
paralysis were found to be independent factors significant in prolonging hospital stay. Diabe-
tes with chronic complications was independently associated with intensive care unit admis-
sion. In addition, underlying congestive heart failure (odds ratio [OR], 1.724; P = 0.003),
dementia (OR, 1.598; P = 0.012), diabetes with and without chronic complications (OR,
1.821; P = 0.002 and OR, 1.518; P = 0.022, respectively), renal disease (OR, 2.299; P =
0.002), and malignancy (OR, 1.529; P = 0.039) were significant factors associated with death,
even after adjustments. Underlying diseases were significant independent factors of the poor
prognosis in patients with COVID-19. The effects were variable according to the type of under-
lying disease and clinical outcome. Therefore, patients with COVID-19 with underlying dis-
eases should be monitored more closely because they are more at risk of a poor prognosis.
Introduction
Coronavirus disease-19 (COVID-19), as named by the World Health Organization (WHO),
has rapidly spread across the world. The WHO has announced that old age and underlying
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medical conditions are major risk factors for a poor prognosis in patients with COVID-19,
based on simple unadjusted values (accessible at: https://www.who.int/docs/default-source/
coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf). There are several reasons
why underlying diseases may affect prognosis in patients with COVID-19. First, an underlying
disease affects the immunity, nutritional status, and general well-being of the patient—factors
that play a critical role in overcoming infections, including COVID-19 [1]. Second, the medi-
cations prescribed for underlying diseases might limit the use of pharmacologic agents against
COVID-19 because of possible drug-to-drug interactions or toxicity from concurrent drug use
[2]. Third, underlying diseases are more commonly found in the older population; therefore,
COVID-19 can cause lethal outcomes in old age [3].
Recent studies have revealed the prevalence of underlying diseases in patients with
COVID-19 and in those who died from the disease [4,5]. Other studies have shown that the
mortality rate was increased from the COVID-19 pandemic based on underlying diseases [6].
However, to the best of our knowledge, there have been no studies on 1) whether underlying
diseases are independent risk factors for a poor prognosis, even after adjusting for age, sex,
and other medical conditions; 2) which underlying diseases significantly affect the prognosis
of patients with COVID-19; and 3) which type of COVID-19 clinical outcomes, such as hospi-
tal costs and prolonged hospital stay, are affected by underlying diseases. Further epidemiolog-
ical data are urgently needed to increase the awareness of the association between underlying
diseases and COVID-19 and to define which diseases pose a higher risk of poor prognosis.




The Ministry of Health and Welfare of Korea and Health Insurance Review and Assessment
Service (HIRA) of South Korea came up with the world’s first de-identified nationwide
COVID-19 medical claims data that included the entire South Korean population (accessible
at https://hira-covid19.net). They released the de-identified list of 7,590 patients confirmed as
having COVID-19 via an RNA polymerase chain reaction test conducted up until May 15,
2020. All 7,590 patients were included in this study. The diagnostic codes for COVID-19 in the
HIRA claims data are as follows: B34.2, coronavirus infection in unspecified area; B97.2, coro-
navirus as the cause of other diseases in other chapters; U18, tentative designation or emer-
gency use of a new disease in South Korea; U18.1, novel coronavirus infection; and U07.1,
COVID-19.
South Korea has a unique national health insurance system that provides insurance for all
its citizens. All the medical records and visits are logged in the claims data. HIRA also provided
data on the patients with COVID-19’ history of availing medical services for the past 3 years
(using finalized claims data, from January 2017 to May 2020). We collected these claims data
to analyze the prevalence of underlying disease and clinical outcomes in the patients with
COVID-19.
Underlying disease and Charlson’s Comorbidity Index
We classified 17 underlying diseases (myocardial infarction, congestive heart failure, periph-
eral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheuma-
tologic disease, peptic ulcer disease, mild liver disease, diabetes without chronic complications,
diabetes with chronic complications, paralysis such as hemiplegia or paraplegia, renal disease,
malignancy including leukemia and lymphoma, moderate or severe liver disease, metastatic
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solid tumor, and acquired immune deficiency syndrome/human immunodeficiency virus)
that are known to affect mortality rates and frequently used to calculate Charlson’s Comorbid-
ity Index (CCI) [7]. These underlying diseases were defined by selecting the diagnostic codes
that showed up at least once in the patient’s claim data from January 1, 2019 to December 31,
2019; the said codes, used to define the comorbidities were based on widely-accepted guide-
lines by HIRA (accessible at https://opendata.hira.or.kr/op/opb/selectRfrm.do?rfrmTpCd=
&searchCnd=&searchWrd=&sno=11200&pageIndex=1). The CCI, which facilitates the pre-
diction of prognosis and mortality, was calculated as previously described, and according to
the HIRA guidelines (S1 Table) [7,8].
Clinical outcomes
To study the clinical outcomes, we evaluated mortality, admission to intensive care unit (ICU),
duration of admission, and total hospital cost for COVID-19 treatment. Mortality and ICU
admission were defined based on the associated intervention codes and medical records, respec-
tively. Duration of admission was defined as the length of hospital stay from admission to dis-
charge for a patient with COVID-19. Total hospital cost was defined as the sum of the expenses
incurred for all the medical claims records during the treatment period for COVID-19.
Ethics
This study was approved by the Institutional Review Board of Gangnam Severance Hospital
(number: 3-2020-0067). The informed consent requirement was waived due to the minimal
risk and retrospective nature of this study using data from the databases.
Statistical analyses
We used a chi-square test to define significant differences in mortality rates among patients
grouped according to underlying diseases. We used linear and logistic regression analyses to
define the risk factors for the clinical outcomes. The data were analyzed using SAS Enterprise
version 6.1 (SAS Institute Inc., Cary, NC, USA). A P<0.05 was used to indicate statistical
significance.
Results
Clinical characteristics and outcomes of patients with COVID-19
There were 7,590 patients with COVID-19 included in this study. The majority of patients with
COVID-19 were in the 20–29 years age group, followed by those in the 50–59- and 60–69-years
age groups (24.4%, 19.8%, and 14.0%, respectively). The patients with COVID-19 were predom-
inantly females (59.2%). Among the 17 underlying diseases, chronic pulmonary disease
(44.6%), mild liver disease (36.2%), and peptic ulcer disease (32.1%) were the most prevalent.
The total mortality rate was 3.0% in this study. Patients <60 years old showed a relatively
low mortality rate (0–0.9%); while those>60 years old showed higher mortality rates (60–69
years old, 3.4%;�70 years old, 18.0%). The mortality rate in males (3.9%) was significantly
higher than that in females (2.4%; P<0.001). The mortality rate in people with underlying dis-
eases (except acquired immune deficiency syndrome) was significantly higher (4.4–19.1%)
than that in people without underlying diseases (Table 1).
Significant factors for mortality
All the variables except that of having acquired immune deficiency syndrome were found to be
significant factors that influenced mortality in univariate analysis. After adjusting for other
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Table 1. Clinical characteristics and outcomes of patients with COVID-19.
Parameters N (%) Mortality (%)
Age (years)
0–9 82 (1.1%) 0 (0.0%)
10–19 346 (4.6%) 0 (0.0%)
20–29 1,855 (24.4%) 0 (0.0%)
30–39 776 (10.2%) 2 (0.3%)
40–49 1,003 (13.2%) 1 (0.1%)
50–59 1,503 (19.8%) 14 (0.9%)
60–69 1,061 (14.0%) 36 (3.4%)
70+ 964 (12.0%) 174 (18.0%)
Sex
Male 3,095 (40.8%) 121 (3.9%)






Prevalence of underlying disease
Myocardial infarction 199 (2.6%) 19 (9.6%)
Congestive heart failure 507 (6.7%) 85 (16.8%)
Peripheral vascular disease 1,064 (14.0%) 90 (8.5%)
Cerebrovascular disease 787 (10.4%) 84 (10.7%)
Dementia 568 (7.5%) 110 (19.4%)
Chronic pulmonary disease 3,388 (44.6%) 151 (4.5%)
Rheumatologic disease 561 (7.4%) 25 (4.5%)
Peptic ulcer disease 2,437 (32.1%) 108 (4.4%)
Mild liver disease 2,747 (36.2%) 132 (4.8%)
Diabetes without chronic complications 1,775 (23.4%) 146 (8.2%)
Diabetes with chronic complications 506 (6.7%) 70 (13.8%)
Paralysis (hemiplegia or paraplegia) 145 (1.9%) 24 (16.6%)
Renal disease 162 (2.1%) 31 (19.1%)
Malignancy 557 (7.3%) 53 (9.5%)
Moderate or severe liver disease 26 (0.3%) 3 (11.5%)
Metastatic solid tumor 61 (0.8%) 7 (11.5%)
Acquired immune deficiency syndrome 7 (0.1%) 1 (14.3%)
Prognosis
Total hospital cost (dollars�) 4,293.4±5,549.1#
Duration of admission (days) 20.1±12.2#
Admission to ICU 215 (2.8%)
Mortality 227 (3.0%)
Total 7,590 227 (3.0%)
� 1 dollar = 1,228.40 Korean Won as of June 1, 2020.
# mean±standard deviation.
Text in bold means a statistically significant difference.
COVID-19, coronavirus disease; ICU, intensive care unit.
https://doi.org/10.1371/journal.pone.0254258.t001
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factors, old age (odds ratio [OR], 1.114; 95% confidence interval [CI], 1.097–1.131; P<0.001)
and male sex (OR for female, 0.385; 95% CI, 0.280–0.529; P<0.001) were revealed to be signifi-
cant risk factors for death. Patients with COVID-19 with underlying congestive heart failure
(OR, 1.724; 95% CI, 1.211–2.456; P = 0.003), dementia (OR, 1.598; 95% CI, 1.108–2.305;
P = 0.012), diabetes with or without chronic complications (OR, 1.821; 95% CI, 1.255–2.644;
P = 0.002 and OR, 1.518; 95% CI, 1.063–2.169; P = 0.022, respectively), renal disease (OR,
2.299; 95% CI, 1.371–3.858; P = 0.002), and/or malignancy (OR, 1.529; 95% CI, 1.022–2.257;
P = 0.039) were significantly at higher risk of death (Table 2 and S1 Fig).
Significant factors for ICU admission
Univariate analysis showed that age, sex, and underlying diseases—except moderate or severe
liver diseases and acquired immune deficiency syndrome—were significant factors that influ-
enced ICU admission. Older patients (OR, 1.050; 95% CI, 1.039–1.061; P<0.001), males (OR
for female, 0.518; 95% CI, 0.389–0.689; P<0.001), and patients with diabetes with chronic
complications (OR, 1.811; 95% CI, 1.241–2.642; P = 0.002) were significantly at risk of ICU
admission in multivariate analysis (Table 3).
Significant factors affecting duration of hospital stay
Age and underlying diseases—except rheumatologic disease, moderate or severe liver diseases,
and acquired immune deficiency syndrome—were found to be significant factors that influ-
enced the duration of hospital stay in univariate analysis. According to the multivariate
Table 2. Significant factors for mortality.
Parameters Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.127 1.114–1.141 <0.001 1.114 1.097–1.131 <0.001
Sex (female) 0.594 0.45–0.774 <0.001 0.385 0.280–0.529 <0.001
Prevalence of underlying disease
Myocardial infarction 3.645 2.228–5.965 <0.001 0.616 0.342–1.108 0.106
Congestive heart failure 9.846 7.395–13.108 <0.001 1.724 1.211–2.456 0.003
Peripheral vascular disease 4.310 3.276–5.670 <0.001 1.063 0.761–1.484 0.721
Cerebrovascular disease 5.566 4.205–7.368 <0.001 0.779 0.540–1.125 0.184
Dementia 14.174 10.745–18.697 <0.001 1.598 1.108–2.305 0.012
Chronic pulmonary disease 2.532 1.915–3.349 <0.001 1.208 0.867–1.684 0.264
Rheumatologic disease 1.576 1.031–2.411 0.036 1.144 0.700–1.870 0.592
Peptic ulcer disease 1.962 1.505–2.557 <0.001 0.831 0.604–1.143 0.255
Mild liver disease 2.523 1.930–3.298 <0.001 0.856 0.610–1.200 0.366
Diabetes without chronic complications 6.345 4.810–8.371 <0.001 1.518 1.063–2.169 0.022
Diabetes with chronic complications 7.084 5.259–9.542 <0.001 1.821 1.255–2.644 0.002
Paralysis (hemiplegia or paraplegia) 7.076 4.469–11.205 <0.001 1.703 0.980–2.959 0.059
Renal disease 8.731 5.758–13.241 <0.001 2.299 1.371–3.858 0.002
Malignancy 4.146 3.009–5.713 <0.001 1.520 1.022–2.257 0.039
Moderate or severe liver disease 4.274 1.274–14.339 <0.001 1.482 0.328–6.694 0.609
Metastatic solid tumor 4.307 1.938–9.572 <0.001 2.112 0.787–5.667 0.138
Acquired immune deficiency syndrome 5.426 0.651–45.253 0.118 7.080 0.462–108.575 0.160
The text in bold means statistically significant difference in multivariate analysis.
OR, odds ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0254258.t002
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analysis results, the duration of hospital stay was significantly lengthened when patients were
old (β coefficient, 0.065; P<0.001), had concomitant cerebrovascular disease (β coefficient,
1.612; P = 0.002), chronic pulmonary disease (β coefficient, 0.831; P = 0.004), or paralysis (β
coefficient, 3.285; P = 0.002) (Table 4).
Significant factors influencing total hospital cost
We determined that the significant factors that contributed to total hospital cost in Korean
Won such as age, sex, and underlying diseases—except for moderate or severe liver diseases
and acquired immune deficiency syndrome—impacted total hospital costs in univariate analy-
sis. In multivariate analysis, old age (β coefficient, 60,885; P<0.001) and being male (female β
coefficient, -893,143; P<0.001) were risk factors for increased total hospital cost. Congestive
heart failure (β coefficient, 1,165,577; P<0.001), chronic pulmonary disease (β coefficient,
453,242; P = 0.004), diabetes without chronic complications (1,026,449; P<0.001), renal dis-
ease (β coefficient, 1,789,702; P = 0.001), malignancy (β coefficient, 922,209; P = 0.003), and
metastatic solid tumor (β coefficient, 2,582,275; P = 0.004) were significant factors that
increased hospital cost (Table 5).
Discussion
The prognosis of COVID-19 was independently affected by underlying diseases, even after
adjusting for age, sex, and other medical conditions. Underlying diseases are frequent in old
age. In addition, some underlying diseases are significantly associated with other underlying
Table 3. Significant factors for ICU admission.
Parameters Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.056 1.048–1.065 <0.001 1.050 1.039–1.061 <0.001
Sex (female) 0.567 0.432–0.745 <0.001 0.518 0.389–0.689 <0.001
Prevalence of underlying disease
Myocardial infarction 2.272 1.247–4.141 0.007 0.695 0.362–1.335 0.275
Congestive heart failure 3.842 2.723–5.422 <0.001 1.209 0.814–1.796 0.347
Peripheral vascular disease 2.896 2.154–3.894 <0.001 1.097 0.785–1.535 0.587
Cerebrovascular disease 3.201 2.339–4.382 <0.001 1.031 0.705–1.507 0.876
Dementia 3.364 2.387–4.741 <0.001 0.771 0.510–1.164 0.216
Chronic pulmonary disease 1.715 1.304–2.258 <0.001 1.087 0.806–1.466 0.585
Rheumatologic disease 1.759 1.156–2.675 0.008 1.229 0.790–1.912 0.362
Peptic ulcer disease 1.839 1.400–2.415 <0.001 1.032 0.765–1.391 0.836
Mild liver disease 2.283 1.737–3.001 <0.001 0.985 0.718–1.352 0.926
Diabetes without chronic complications 3.808 2.898–5.005 <0.001 1.294 0.919–1.821 0.14-
Diabetes with chronic complications 5.137 3.721–7.093 <0.001 1.811 1.241–2.642 0.002
Paralysis (hemiplegia or paraplegia) 3.219 1.754–5.907 <0.001 1.102 0.566–2.146 0.776
Renal disease 4.281 2.540–7.215 <0.001 1.434 0.813–2.531 0.213
Malignancy 3.132 2.203–4.453 <0.001 1.406 0.946–2.091 0.092
Moderate or severe liver disease 2.876 0.675–12.248 0.153 1.364 0.301–6.188 0.687
Metastatic solid tumor 3.821 1.627–8.973 0.002 1.810 0.702–4.665 0.219
Acquired immune deficiency syndrome 0.000 0.000–999.999 0.976 0.000 0.000–999.999 0.983
Text in bold means a statistically significant difference in the multivariate analysis.
ICU, intensive care unit; OR, odds ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0254258.t003
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diseases (for example, cerebrovascular disease and dementia; myocardial infarction and
peripheral vascular disease). Therefore, a detailed analysis with adjustments was needed to
determine whether underlying diseases were independent risk factors for the severity of
COVID-19 presentation. To the best of our knowledge, this is the first study to confirm that
underlying diseases are independent risk factors for poor prognosis of COVID-19, after adjust-
ing for age, sex, and other chronic conditions. In addition, we also found that the prognosis
and outcomes of patients with COVID-19 varied according to the type of underlying diseases
that the patients had.
Underlying renal disease had the greatest effect on COVID-19 prognosis, especially death
(OR, 2.299) and increased hospital cost. In renal diseases, the disturbance of toll-like receptors
and alterations in the immune system contribute to immunodepression in those with said
affliction [9]; such patients are more susceptible to infection and have difficulty recovering
when infected. In addition, impaired renal function serves as a contraindication to the admin-
istration of pharmacologic treatment against COVID-19; or the dose of medication needs to
be adjusted based on the renal function; this can lead to suboptimal treatment outcomes.
Diabetes is the next underlying disease that was found to have a significant effect on death
(OR, 1.518–1.821), total hospital cost, and ICU admission of patients with COVID-19. A
recent study reported that patients with diabetes are highly susceptible to COVID-19, and vari-
ous mechanisms were proposed [10]. Diabetes can cause multiple metabolic and vascular
abnormalities, affecting the patient’s response to pathogens [11]. Uncontrolled hyperglycemia
is a risk factor for infections (e.g., pneumonia and influenza) and subsequent poor outcomes;
therefore, strict glycemic control is critical for infection control [11–13]. Interestingly, our
findings that diabetes increases the risk for poor prognosis in COVID-19 is consistent with
Table 4. Significant factors for admission duration.
Parameters Univariate analysis Multivariate analysis
β coefficient P-value β coefficient P-value
Age (years) 0.097 <0.001 0.065 <0.001
Sex (female) 0.437 0.125 0.219 0.440
Prevalence of underlying disease
Myocardial infarction 2.790 0.001 0.081 0.929
Congestive heart failure 3.746 <0.001 0.686 0.259
Peripheral vascular disease 2.075 <0.001 -0.556 0.205
Cerebrovascular disease 4.345 <0.001 1.612 0.002
Dementia 4.123 <0.001 0.308 0.611
Chronic pulmonary disease 1.667 <0.001 0.831 0.004
Rheumatologic disease 0.835 0.118 -0.462 0.395
Peptic ulcer disease 1.540 <0.001 0.172 0.584
Mild liver disease 2.031 <0.001 0.284 0.392
Diabetes without chronic complications 2.932 <0.001 0.577 0.152
Diabetes with chronic complications 3.457 <0.001 0.554 0.365
Paralysis (hemiplegia or paraplegia) 6.738 <0.001 3.285 0.002
Renal disease 4.139 <0.001 1.651 0.093
Malignancy 2.940 <0.001 1.038 0.069
Moderate or severe liver disease -0.392 0.870 -2.589 0.276
Metastatic solid tumor 3.910 0.013 1.521 0.347
Acquired immune deficiency syndrome -5.984 0.194 -7.954 0.081
Text in bold means a statistically significant difference in the multivariate analysis.
https://doi.org/10.1371/journal.pone.0254258.t004
PLOS ONE Effects of underlying disease in COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0254258 July 19, 2021 7 / 13
similar previous studies in other coronavirus infections such as middle east respiratory syn-
drome and severe acute respiratory syndrome [12,14–16].
Congestive heart failure was also found to be a significant predictive factor for poor clinical
outcomes in COVID-19, including death (OR, 1.724) and increased total hospital cost. Patients
with congestive heart failure frequently present with dyspnea, cough, edema, and pleural effu-
sion. These symptoms are similar to those of COVID-19; hence, symptoms from heart failure,
especially dyspnea, can be aggravated in the presence of that infection. In addition, congestive
heart failure is associated with an increase in endotoxins and cytokines [17] that can trigger
the cytokine storm observed in COVID-19 that can prove fatal. Therefore, COVID-19-infected
patients with congestive heart failure should be carefully monitored.
Dementia is another significant factor associated with death (OR, 1.598). Our findings are
in keeping with those of studies on dementia being associated with prognosis in COVID-19;
one such study reported how the presence of the ApoE e4e4 allele—the gene associated with
dementia—puts a patient at risk for severe COVID-19 [18,19]. Also, patients with dementia
might be uncooperative in terms of expelling sputum, allowing for monitoring of vital signs,
maintaining oxygen support, and even the medication intake. These factors may lead to poor
outcomes of COVID-19 in patients with dementia.
Malignancy was revealed to be one of the important risk factors for mortality (OR, 1.520)
and increased hospital cost. Moreover, metastasis from solid tumors was also a risk factor
affecting those outcomes. Since malignancy alters cell-mediated immunity, patients with can-
cer—especially those in the advanced stages—become immunocompromised, and hence more
susceptible to infections, including those of viral etiology [20,21]. In addition,
Table 5. Significant factors for the total hospital cost.
Parameters Univariate analysis Multivariate analysis
β coefficient P-value β coefficient P-value
Age (years) 74,781 <0.001 60,885 <0.001
Sex (female) -693,714 <0.001 -893,143 <0.001
Prevalence of underlying disease
Myocardial infarction 1,374,958 0.005 -864,257 0.083
Congestive heart failure 3,144,068 <0.001 1,165,577 <0.001
Peripheral vascular disease 1,740,131 <0.001 30,392 0.900
Cerebrovascular disease 1,953,548 <0.001 78,942 0.787
Dementia 2,087,732 <0.001 -606,724 0.069
Chronic pulmonary disease 1,008,164 <0.001 453,242 0.004
Rheumatologic disease 1,022,204 <0.001 140,774 0.638
Peptic ulcer disease 926,043 <0.001 -2451 0.989
Mild liver disease 1,285,736 <0.001 -262,483 0.151
Diabetes without chronic complications 2,559,127 <0.001 1,026,449 <0.001
Diabetes with chronic complications 2,713,274 <0.001 408,814 0.225
Paralysis (hemiplegia or paraplegia) 1,499,017 0.009 -628,917 0.287
Renal disease 3,860,969 <0.001 1,789,702 0.001
Malignancy 2,524,916 <0.001 922,209 0.003
Moderate or severe liver disease 903,871 0.500 -938,758 0.473
Metastatic solid tumor 4,560,340 <0.001 2,582,275 0.004
Acquired immune deficiency syndrome -18,179 0.994 -1,263,459 0.615
Text in bold means a statistically significant difference in the multivariate analysis.
https://doi.org/10.1371/journal.pone.0254258.t005
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immunosuppressive therapy used in cancer treatment may also contribute to failure of treat-
ment for COVID-19.
Cerebrovascular disease and paralysis (hemiplegia or paraplegia) were revealed to be risk
factors for longer hospital stay. In COVID-19, the route of infection is usually via the respira-
tory tract, and the cause of the death is usually a respiratory problem [22]. Patients with cere-
brovascular disease or paralysis might be difficult to manage in the setting of COVID-19, as
they might have problems in complying with management, including the expectoration of spu-
tum. This may delay extubation and discharge.
Chronic pulmonary disease was also a significant factor found to contribute to increased
hospital cost and prolonged hospital stay. COVID-19 is a respiratory infection, and therefore,
the fact that prognosis of COVID-19 is poor in patients with chronic pulmonary disease is
quite natural. However, the impact of chronic pulmonary disease on the COVID-19 were less
significant compared to those of other underlying diseases. The prevalence of chronic pulmo-
nary disease in this study was excessively high (44.6%). We followed the definition of chronic
pulmonary disease as suggested in the HIRA guidelines; however, some diagnostic codes for
chronic pulmonary disease in our data set might represent temporary pulmonary disease. The
relatively high prevalence of chronic pulmonary disease in our study may have decreased the
impact of that on the prognosis of patients with COVID-19. Further studies with a different
definition of chronic pulmonary disease are needed to define its effects on the prognosis of
COVID-19.
Unlike the other underlying diseases, acquired immune deficiency syndrome and moderate
or severe liver disease did not show any significant effects on prognosis after adjustment. How-
ever, the number of patients with acquired immune deficiency syndrome (n = 7) and moderate
or severe liver disease (n = 26) included in this study was too small to adequately analyze their
effect on the prognosis of COVID-19. To the best of our knowledge, there are only a few stud-
ies investigating the relationship between acquired immune deficiency syndrome and
COVID-19. One case series reported that the mortality rate was not high (as 5 of 5 survived)
and that only 1% of patients with COVID-19 who required hospitalization had acquired
immune deficiency syndrome [23]. Further research on the relationship between acquired
immune deficiency syndrome and COVID-19 is needed.
As expected, age was the single most important risk factor for increased hospital cost, pro-
longed hospital stay, ICU admission, and mortality in this study. This finding is consistent
with those of previous studies [24–28]. We also found that the male sex was also an important
risk factor in the prognosis of COVID-19. Although several studies have revealed sex dispari-
ties in the prevalence and prognosis of COVID-19 [26,29,30], a recent review reported that
mortality was higher in males than in females, similar to the results of this study. The differ-
ences in angiotensin converting enzyme 2 and transmembrane serine protease 2 regulation
and immune response to viral infections between males and females are emerging as the
potential mechanisms [29]. The cell associated forms of the above two molecules are known to
be important proteins in the intracellular invasion of severe acute respiratory syndrome coro-
navirus 2, and various studies have reported that sex hormones, such as estrogen, regulate
these two proteins [31–35].
A strength of this study is its national coverage, which includes 7,590 patients with COVID-
19. Also, to the best of our knowledge, this study is the first to reveal the variable effects of
underlying diseases on the prognosis of patients with COVID-19.
However, there are also some limitations to this study. First, this study did not include
important clinical data such as physical examination findings and laboratory findings that may
have affected the results. Second, the diagnosis of underlying diseases was simply defined by
diagnostic codes. Therefore, the prevalence of underlying disease was relatively high—
PLOS ONE Effects of underlying disease in COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0254258 July 19, 2021 9 / 13
especially chronic pulmonary disease—compared with that in previous studies [4]. South
Korea has a national insurance system, and therefore, medical costs are relatively low. Given
this, people in South Korea are admitted to the hospital for trivial symptoms such as mild
cough or heartburn. This might explain why the prevalence of some underlying diseases,
including chronic pulmonary and peptic ulcer diseases, seems to be higher than we expected
in general population. Lastly, in the future, further studies with a larger sample size are needed
to further define the effects of rare underlying diseases, including acquired immune deficiency
syndrome, on COVID-19 prognosis.
Conclusion
In conclusion, each underlying disease in this study had an independent variable effect on the
clinical outcomes of COVID-19 after adjustments for age, sex, and other chronic conditions.
Renal disease, diabetes, congestive heart failure, dementia, and malignancy proved to be risk
factors for mortality. Cerebrovascular disease and paralysis prolonged duration of hospital
stay. Chronic pulmonary disease increased total hospital cost and delayed the discharge date.
In conclusion, patients with underlying diseases must be monitored more carefully because
they are at a higher risk of poor outcomes while admitted for COVID-19.
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